Kevin Quon
Insider ownership, small-cap, long-term horizon, dividend investing

Insys Therapeutics: Finding No Pain In This Specialty Pharmaceutical Company

Having cancer is inevitably a painful experience. While background pain medication is often used to alleviate the occurrence of pain, sometimes the onset of pain can be unpredictable and sudden. Breakthrough cancer pain, also known as BTCP, is characterized by this very concept. BTCP is the onset of intense pain, which can peak in severity over three to five minutes despite the active nature of background pain medication.

One company that has recently developed a proprietary product to counter the effects of BTCP is Insys Therapeutics, Inc. (NASDAQ:INSY). In January 2012, Insys received marketing approval from the U.S. Food and Drug Administration for its proprietary drug Subsys. Subsys is a single-use product that delivers a dose of...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details